Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis

Abstract

Objective

Multiple studies investigated preclinical markers of peripheral vascular damage in acromegaly (ACRO) reporting discordant results. The aim of this study was to run a meta-analysis to examine whether intima media thickness (IMT), flow mediated dilation (FMD) and arterial pulse wave velocity (PWV) are affected in acromegalic patients and to assess the impact of effective treatment of growth hormone excess on these outcomes.

Study selection

Twenty-seven studies comparing ACRO vs control (CON) populations and active (ACT) vs inactive (INACT) ACRO were included in the meta-analysis.

Data synthesis

ACRO compared to CON have higher IMT (ES = 0.83, 95% C.I. 0.35–1.30), p = 0.001, impaired FMD (ES = − 1.59, 95% C.I. − 2.33 to − 0.85, p < 0.0001) and higher PWV (ES = 0.76 95% C.I. 0.37–1.16, p = 0.0001). When patients with ACT vs INACT disease were considered IMT was higher (ES = 0.43, 95% C.I. 0.02–0.84, p = 0.041) and FMD was impaired (ES = − 0.66, 95% C.I. − 1.28 to 0.04, p = 0.038) in ACT patients. Meta-regression analysis of studies comparing IMT in ACT vs INACT acromegalic patients showed a significant and inverse association between the effect size and the percent of hypertensive (p = 0.025) and diabetic (p = 0.041) patients.

Conclusions

IMT, FMD and arterial stiffness are impaired in acromegaly showing that these patients may be at increased risk of atherosclerosis. In patients with active disease these preclinical markers of atherosclerosis are worse compared to patients with inactive disease but the role of diabetes and hypertension is prevailing on growth hormone excess.